## Jesðs Fidel Salazar-GonzÃ;lez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9396304/publications.pdf

Version: 2024-02-01

39 papers

9,067 citations

218592 26 h-index 302012 39 g-index

41 all docs

41 docs citations

41 times ranked

7118 citing authors

#	Article	IF	CITATIONS
1	Characterization of Near Full-Length Transmitted/Founder HIV-1 Subtype D and A/D Recombinant Genomes in a Heterosexual Ugandan Population (2006–2011). Viruses, 2022, 14, 334.	1.5	4
2	Infection with HIV-1 subtype D among acutely infected Ugandans is associated with higher median concentration of cytokines compared to subtype A. IJID Regions, 2022, 3, 89-95.	0.5	1
3	HIV-1 Gag-Pol Sequences from Ugandan Early Infections Reveal Sequence Variants Associated with Elevated Replication Capacity. Viruses, 2021, 13, 171.	1.5	2
4	Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda. Journal of Antimicrobial Chemotherapy, 2020, 75, 1280-1289.	1.3	11
5	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nature Communications, 2018, 9, 1928.	5.8	83
6	HIV-1–Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection. Journal of Immunology, 2016, 196, 3276-3286.	0.4	31
7	Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes. Pathogens and Immunity, 2016, 1, 129.	1.4	9
8	Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. Retrovirology, 2013, 10, 3.	0.9	39
9	Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. Journal of Virology, 2013, 87, 7218-7233.	1.5	119
10	Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. Retrovirology, 2013, 10, 88.	0.9	9
11	Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin $\hat{l}\pm4\hat{l}^2$ 7. PLoS Pathogens, 2012, 8, e1002686.	2.1	140
12	Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages. Journal of Virology, 2012, 86, 2715-2728.	1.5	291
13	Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy. PLoS ONE, 2011, 6, e19617.	1.1	65
14	HIV gene expression from intact proviruses positioned in bacterial artificial chromosomes at integration sites previously identified in latently infected T cells. Virology, 2011, 410, 151-160.	1.1	3
15	HIV-Specific Functional Antibody Responses in Breast Milk Mirror Those in Plasma and Are Primarily Mediated by IgG Antibodies. Journal of Virology, 2011, 85, 9555-9567.	1.5	86
16	Origin and Evolution of HIV-1 in Breast Milk Determined by Single-Genome Amplification and Sequencing. Journal of Virology, 2011, 85, 2751-2763.	1.5	57
17	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. PLoS Pathogens, 2011, 7, e1001273.	2.1	90
18	Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections. PLoS Pathogens, 2011, 7, e1002209.	2.1	114

#	Article	IF	Citations
19	A rev1–vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev–vpu–env cassettes and reduces virion infectivity in pseudotyping assays. Virology, 2010, 397, 346-357.	1.1	20
20	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathogens, 2010, 6, e1000890.	2.1	263
21	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1253-1272.	4.2	562
22	Modeling sequence evolution in acute HIV-1 infection. Journal of Theoretical Biology, 2009, 261, 341-360.	0.8	162
23	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1273-1289.	4.2	684
24	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7552-7557.	3.3	1,708
25	Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing. Journal of Virology, 2008, 82, 3952-3970.	1.5	540
26	Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology, 2007, 360, 218-234.	1.1	67
27	Impact of opportunisticMycobacterium tuberculosis infection on the phenotype of peripheral blood T cells of AIDS patients. Journal of Clinical Laboratory Analysis, 2006, 20, 80-86.	0.9	4
28	Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa. Journal of Virology, 2006, 80, 11776-11790.	1.5	334
29	Employment of microarray analysis to characterize biologic differences associated with tropism-modified adenoviral vectors: utilization of non-native cellular entry pathways. Cancer Gene Therapy, 2005, 12, 162-174.	2.2	7
30	Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2005, 79, 10108-10125.	1.5	1,025
31	Antibody neutralization and escape by HIV-1. Nature, 2003, 422, 307-312.	13.7	2,233
32	Macrophage HIV-1 infection and the gastrointestinal tract reservoir. Journal of Leukocyte Biology, 2003, 74, 642-649.	1.5	92
33	Quercetin inhibits human vascular smooth muscle cell proliferation and migration. Surgery, 2002, 131, 198-204.	1.0	46
34	Quantification of cytokine mRNA in peripheral blood mononuclear cells using branched DNA (bDNA) technology. Journal of Immunological Methods, 1998, 215, 123-134.	0.6	14
35	Circulating CD8 T Cells Show Increased Interferon- $\hat{I}^3$ mRNA Expression in HIV Infection. Cellular Immunology, 1997, 178, 91-98.	1.4	32
36	Relationship of Plasma HIV-RNA Levels and Levels of TNF- $\hat{l}\pm$ and Immune Activation Products in HIV Infection. Clinical Immunology and Immunopathology, 1997, 84, 36-45.	2.1	54

#	Article	IF	CITATIONS
37	Immune sensitization against epidermal antigens in polymorphous light eruption. Journal of the American Academy of Dermatology, 1991, 24, 70-73.	0.6	34
38	Histamine Blocks Interleukin 2 (IL-2) Gene Expression and Regulates IL-2 Receptor Expression. Immunopharmacology and Immunotoxicology, 1990, 12, 345-362.	1.1	13
39	HIVâ€induced B Cell Stimulatory Factor 2/Interleukinâ€6 (BSF2/IL6) Production <sup>a</sup> . Annals of the New York Academy of Sciences, 1989, 557, 521-524.	1.8	O